Pathogenesis(pgns) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mel Spivak who wrote (107)	10/27/1998 3:02:00 PM
From: margie	Read Replies (4) of 228

Today's IBD column discusses Pathogenesis in "The Real "Most Active" column.* "Pathogenesis rose 1 to 39 on above average volume. The stock, which has been basing for a year, closed 3% below its April 30 high." "In December '97, PathoGenesis received FDA approval for a new drug, TOBI, an inhalable form of the antibiotic tobramycin used to fight bacterial infections in cystic fibrosis patients." "After Monday's close, the company reported a third-quarter loss of 18 cents a share after licensing an aerosolized drug candidate for $4 million." "Sales of Tobi were $14.8 million in the current quarter, up 9% from the second quarter." *Real Most Active: Stocks are stocks that are >$16, EPS+RS=or>110 and next years earnings >18%+ (Based on yesterdays close) FYI: EPS/RS/Acc-Distr 76/92/A Congratulations!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next